AI Score

Unlock

Penumbra Inc. (PEN)

AI Score

Unlock

272.77

12.14 (4.66%)

At close: Mar 14, 2025, 3:59 PM

273.75

0.36%

After-hours: Mar 14, 2025, 06:20 PM EDT

4.66% (1D)

Bid	272.5
Market Cap	10.51B
Revenue (ttm)	1.19B
Net Income (ttm)	13.97M
EPS (ttm)	0.36
PE Ratio (ttm)	757.69
Forward PE	71.39
Analyst	Buy

Ask	274
Volume	267,698
Avg. Volume (20D)	470,466
Open	266.46
Previous Close	260.63
Day's Range	266.24 - 274.63
52-Week Range	148.00 - 310.00
Beta	0.51

About PEN

Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling...

[Show more]

Industry Medical - Devices

Sector Healthcare

IPO Date Sep 18, 2015

Employees 4,500

Stock Exchange NYSE

Ticker Symbol PEN

Website https://www.penumbrainc.com

Full Company Profile

Analyst Forecast

According to 16 analyst ratings, the average rating for PEN stock is "Buy." The 12-month stock price forecast is $305, which is an increase of 11.82% from the latest price.

Stock Forecasts

Next Earnings Release

Penumbra Inc. is scheduled to release its earnings on May 6, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 day ago New

Penumbra shares are trading higher after B of A Se... Unlock content with Pro Subscription

3 weeks ago

+12.03%

Penumbra shares are trading higher after Baird and Morgan Stanley raised their respective price targets on the stock.

News

2 weeks ago · zacks.com

Growing Thrombectomy Business Supports PEN Stock, Macro Issues Ail

Penumbra is still in the early stages of its journey to bring the company's proprietary thrombectomy technologies to patients in the United States and around internationally.

3 weeks ago · zacks.com

Penumbra (PEN) Upgraded to Buy: Here's Why

Penumbra (PEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

3 weeks ago · zacks.com

Penumbra Q4 Earnings & Revenues Top, Margins Expand, Stock Rises

Penumbra reports better-than-expected earnings and revenues in the fourth quarter of 2024.

3 weeks ago · seekingalpha.com

Penumbra, Inc. (PEN) Q4 2024 Earnings Call Transcript

Penumbra, Inc. (NYSE:PEN ) Q4 2024 Earnings Conference Call February 18, 2025 4:30 PM ET Company Participants Cecilia Furlong - Director of Business Development and Investor Relations Adam Elsesser - ...

3 weeks ago · zacks.com

Here's What Key Metrics Tell Us About Penumbra (PEN) Q4 Earnings

The headline numbers for Penumbra (PEN) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estim...

3 weeks ago · zacks.com

Penumbra (PEN) Beats Q4 Earnings and Revenue Estimates

Penumbra (PEN) came out with quarterly earnings of $0.97 per share, beating the Zacks Consensus Estimate of $0.91 per share. This compares to earnings of $0.76 per share a year ago.